Oncology only buys time: 'survival rates' are meaningless, patients die during treatment, and early diagnosis only makes you 'die early'.
Original statement
عشان كده في حاجه اسمها تشخيص مبكر عشان تبقى ميت مبكر
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Oncology only buys time: 'survival rates' are meaningless, patients die during treatment, and early diagnosis only makes you 'die early'.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! لايف مفاجيء (Open source)
- Published
- 5 August 2025
- Timestamp
- 0:16:53 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
- Population concerned
Cancer patients
- Geographic restriction by Elawady
none found
Diverging source versions
انا جاي اعيش 60 سنه اعيش منهم اربع سنين عشان انت ترتاح انت واللي شبهك كيماوي اشعاع لحد ما اموت
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! التراكمي عال و السكر واطيي (Open source)
- Published
- 5 October 2025
- Timestamp
- 0:34:56 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
بيحسبوا نجاحهم في الكيماوي بالبقاء حيا
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- حلقه علميه قويه تواجه التضليل العلمي بالحقيقه (Open source)
- Published
- 17 April 2026
- Timestamp
- 1:26:32 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
Scientific assessment
False – The statement contradicts the robust evidence.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Chemotherapy and radiotherapy give only short survival with suffering; cancer patients die during treatment.
2. What is demonstrably correct?
Survival statistics can be inflated by earlier detection (lead-time bias) and some screening leads to overdiagnosis - a legitimate methodological point; 5-year survival is not the same as cure. Treatment near death often does not help (C-CHM-07). Treatment-related deaths do occur, but they are rare: in the breast-cancer trial overview, deaths without recurrence in the first year were 0.3% vs 0.2% (taxane vs control, women under 70), non-breast-cancer mortality was higher with anthracycline or CMF chemotherapy than with no chemotherapy (RR 1.20 and 1.24), and cardiac mortality was higher with anthracyclines (RR 1.56) (I-CHM-01).
3. What is wrong or exaggerated?
These treatment-related deaths are far outweighed by the benefit: overall mortality was lower with chemotherapy than without (RR 0.84) (I-CHM-01), and radiotherapy after breast-conserving surgery reduced 15-year all-cause mortality by 3.0 percentage points (0.6-5.4) (I-CHM-02). Many treated patients are cured or live long: childhood ALL 5-year survival 90.4% (I-CHM-05); testicular cancer 10-year relative survival 95% (A-CHM-14); 15-year late mortality among 5-year childhood survivors fell to 6.0% (A-CHM-11); 52% 5-year survival in advanced melanoma with immunotherapy (I-CHM-08); US cancer mortality decline averted over 4 million deaths since 1991, partly through improved treatment (I-CHM-12).
4. What remains unclear?
Survival and cure rates differ by cancer type, stage and country; adult Egyptian survival data were not reviewed. The size of lead-time and overdiagnosis effects varies by cancer and screening programme.
5. Which studies support it?
Only for the narrow methodological point: from 1950 to 1995, changes in 5-year survival tracked changes in diagnosis (r=+0.49 with incidence) but not changes in mortality (r=0.00) (I-CHM-106); screening can cause overdiagnosis (NLST incidence ratio 1.13; I-CHM-107). Some new drugs add only months (I-CHM-124). None of this supports 'early diagnosis makes you die early'.
6. Which studies contradict it?
I-CHM-01, I-CHM-02, I-CHM-05, I-CHM-08, I-CHM-12, A-CHM-11, A-CHM-14; I-CHM-107 (low-dose CT screening reduced lung-cancer mortality by 20.0% and all-cause mortality by 6.7% in a randomised trial); I-CHM-103 (chemotherapy raised 1-year survival in advanced lung cancer from 20% to 29%); I-CHM-125 (Egypt: 72.1% 5-year survival in children treated for cancer).
7. What applies to Germany and Europe?
Same.
8. What is known about Egypt?
At Children's Cancer Hospital Egypt, 5-year survival of 14,808 children treated for cancer was 72.1% and rose over 2007-2017, although it remained about 9-11 points below England and the USA (I-CHM-125).
9. What practical conclusion is appropriate?
Ask the oncologist for absolute survival and cure probabilities for the specific cancer and stage.
Assessment details
- Rationale for certainty of evidence
Long-term cure and survival data from randomised trials and registries.
- Source quality
Machine transcripts.
- Regional transferability
High.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.
Research question: Does oncology only 'buy time', are survival statistics meaningless, and does early diagnosis only make people 'die early'?
Research question in detail (PICO)
- Population
- People with or at risk of cancer
- Intervention or exposure
- Early detection and modern cancer treatment
- Comparison
- Later detection; no treatment
- Geographic scope
- universal; Egyptian data included
- Outcomes
- Cancer mortality
- All-cause mortality
- Cure rates
- Validity of survival statistics
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Why rising cancer survival rates can mislead
Welch HG et al.. JAMA 2000 · PMID 10865276 · DOI 10.1001/jama.283.22.2975 Ecological studyabstract checkednewly addedRising 5-year survival over time tracked rising diagnosis, not falling deaths.
- Actual result
- r=0.00 with mortality change; r=+0.49 with incidence change
- Methodological quality
- moderate (ecological, 20 tumour types)
- Relevance
- indirect: supports caution about survival trends only
- Limitations
- Old data; not about treatment effects
Many new cancer drugs approved without proof of longer or better life
Many new cancer drugs add only months or have unproven benefit.
- Actual result
- OS benefit at approval in 35%; median 2.7 months
- Methodological quality
- moderate
- Relevance
- indirect
- Limitations
- New drugs only
What speaks against the claim?
Lung CT screening trial (NLST)
National Lung Screening Trial Research Team; Aberle DR et al.. N Engl J Med 2011 · PMID 21714641 · DOI 10.1056/NEJMoa1102873 Randomised controlled trialabstract checkednewly addedLung-cancer screening RCT: earlier detection plus treatment reduced lung-cancer and all-cause mortality.
- Actual result
- Lung-cancer mortality -20.0% (6.8-26.7); all-cause -6.7%
- Methodological quality
- high (large RCT, mortality endpoint)
- Relevance
- direct refutation of 'die early'
- Limitations
- Overdiagnosis and false positives
Childhood cancer survival in Egypt
Soliman RM et al.. Int J Cancer 2021 · PMID 32997796 · DOI 10.1002/ijc.33321 Cohort studyabstract checkednewly addedIn Egypt, 72% of children treated for cancer were alive 5 years later, rising over time.
- Actual result
- 5-y OS 72.1%; 69.6% -> 74.2%
- Methodological quality
- moderate (very large hospital cohort)
- Relevance
- direct regional evidence
- Limitations
- No untreated comparator
About 9 in 10 children with leukaemia now survive
Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018 Cohort studyabstract checkedChildhood ALL 5-year survival rose to about 90% with improved treatment.
- Actual result
- 83.7% -> 90.4%
- Methodological quality
- high (cooperative-group cohort)
- Relevance
- direct
- Limitations
- US data
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Modern cancer treatment cures many patients (e.g. most children, testicular cancer) and prolongs life in others; early detection in proven programmes lowers mortality. A legitimate kernel: survival-rate trends can be inflated by lead-time and overdiagnosis, and some new drugs add little.
Why some studies weigh more
Mortality-endpoint RCTs avoid lead-time bias and weigh most; ecological and regulatory analyses support only the methodological caveat.
Is a causal relationship established? Yes, established RCTs with mortality endpoints.
Remaining uncertainty
Degree of overdiagnosis in specific screening programmes.
Justified conclusion
False as stated, with a correct methodological kernel.
Why do studies seem to disagree?
Welch 2000 (survival trends misleading) and NLST (mortality reduced) agree methodologically: survival trends can mislead, which is why mortality in randomised trials is used; on that metric early detection plus treatment saves lives.
Does this depend on the country?
- General biological effects
- Universal methodology and clinical evidence.
- Eating habits
- Not relevant.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant.
- National production conditions
- Not relevant.
- Legal rules
- Not relevant.
- Actual monitoring data
- Egyptian childhood cancer survival 72.1% (I-CHM-125); adult Egyptian survival data not reviewed.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Recompute rate ratio; CI shape – 247/309 = 0.799 (reported 20.0% reduction); reported CI asymmetric on log scale, consistent with interim-monitoring adjustment recalculated
- Interpretation – r=0.00 (mortality) vs +0.49 (incidence): supports lead-time/overdiagnosis caveat, not futility recalculated
- Absolute trend – +4.6 points 5-y OS between periods recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Mortality with early detection and treatment
- Starting level
- high (randomised trials)
- Result
- high
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- WHO: Cancer - fact sheet (2026 (page fetched 2026-10-26)) · Original publication
Many cancers can be cured if detected early and treated effectively; treatment usually includes surgery, radiotherapy and/or systemic therapy; some cancers such as testicular seminoma and childhood leukaemias and lymphomas have high cure rates with appropriate treatment even when spread; palliative care relieves symptoms in advanced cancer. - NCI: Chemotherapy to Treat Cancer (2026 (fetched 2026-10-26)) · Original publication
Chemotherapy can be used to cure cancer, lessen the chance it will return, or stop or slow its growth, and to ease symptoms; it also harms fast-growing healthy cells, causing side effects.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | TITLE:"5-year survival rates" AND TITLE:"evidence of success against cancer" | supporting evidence | 1 | |
| Europe PMC | 26 October 2026 | (TITLE:"lead-time bias" OR TITLE:"overdiagnosis") AND TITLE:"survival" AND (TITLE:"screening") AND PUB_YEAR:[2000 TO 2026] | supporting evidence | 5 | |
| Europe PMC | 26 October 2026 | TITLE:"contribution of cytotoxic chemotherapy to 5-year survival" | supporting evidence | 1 | |
| Europe PMC | 26 October 2026 | TITLE:"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency" | supporting evidence | 2 | |
| Europe PMC | 26 October 2026 | TITLE:"Reduced lung-cancer mortality with low-dose computed tomographic screening" | contradicting evidence | 1 | |
| Europe PMC | 26 October 2026 | TITLE:"Reduced Lung-Cancer Mortality with Volume CT Screening" | contradicting evidence | 2 | |
| Europe PMC | 26 October 2026 | (TITLE:"survival") AND (TITLE:"breast cancer" OR TITLE:"childhood cancer" OR TITLE:"leukemia") AND TITLE:"Egypt" AND PUB_YEAR:[2015 TO 2026] | contradicting evidence | 4 | |
| Europe PMC | 26 October 2026 | TITLE:"chemotherapy" AND TITLE:"supportive care" AND TITLE:"non-small-cell lung cancer" AND (TITLE:"meta-analysis" OR TITLE:"individual patient") | contradicting evidence | 3 |
Open questions
Adult cancer survival in Egypt.
How deeply was this checked?
13 linked studies: 4 checked in full text (4 of them with a structured risk-of-bias assessment), 9 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: False (high)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: False (high)
The legitimate kernel (lead-time and overdiagnosis) is now sourced (I-CHM-106) and acknowledged; mortality-endpoint RCTs and Egyptian survival data confirm the verdict.
New sources: I-CHM-106 I-CHM-107 I-CHM-103 I-CHM-125 I-CHM-123 I-CHM-124
In plain language
Dr. Diaa said that cancer treatment only counts how long people survive and that early diagnosis just makes people 'die early'. It is true that survival statistics must be read carefully, and a small number of patients do die from side effects of treatment. But overall, treated patients die less often than untreated ones in randomised trials. Many patients are cured: about 9 in 10 children with leukaemia and about 95 in 100 men with testicular cancer survive long-term. Cancer death rates have fallen for decades, partly because of better treatment.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (10)
-
Chemotherapy after breast-cancer surgery reduces deaths by about a third
EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5Meta-analysisindependent cross-checkfull text, structured risk-of-bias assessment★ key studyIn 123 trials with 100,000 women, modern regimens cut breast-cancer deaths by about one-third, and overall deaths fell too.
Overall mortality reduced
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare chemotherapy regimens and no chemotherapy.
- How was the study done?
IPD meta-analysis of RCTs.
- How many people, animals or samples were studied?
~100,000 women.
- What was actually found?
~1/3 lower breast-cancer mortality.
- How large was the observed effect?
RR 0.64-0.78 vs none.
- What do the results mean in everyday life?
For many women, chemotherapy substantially raises the chance of survival.
- What are the study's limitations?
Trials versus no chemotherapy are old (median start 1986); a small excess of non-breast-cancer deaths (e.g. heart, leukaemia) occurred; benefit is small when baseline risk is low.
- What does it say about Elawady's specific claim?
Contradicts claims that chemotherapy is useless.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual benefit without risk assessment.
-
Radiotherapy after breast-conserving surgery halves recurrence
EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2Meta-analysisindependent cross-checkfull text, structured risk-of-bias assessment★ key studyRecurrence within 10 years fell from 35% to 19%, and breast-cancer deaths within 15 years from 25% to 21%.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure radiotherapy benefit.
- How was the study done?
IPD meta-analysis.
- How many people, animals or samples were studied?
10,801 women.
- What was actually found?
Recurrence halved; breast-cancer deaths about one-sixth lower; deaths from any cause at 15 years 3.0 percentage points lower.
- How large was the observed effect?
-15.7% recurrence; -3.8% death.
- What do the results mean in everyday life?
Radiotherapy markedly lowers the chance the cancer returns.
- What are the study's limitations?
Older techniques; risk groups derived from the same data; in low-risk node-negative women the gain in survival was small and uncertain.
- What does it say about Elawady's specific claim?
Benefit side.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual benefit size without risk factors.
-
About 9 in 10 children with leukaemia now survive
Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018Cohort studyindependent cross-checkabstract checked★ key study5-year survival in childhood ALL rose to 90.4% by 2000-2005.
90% 5-year survival
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Track ALL survival.
- How was the study done?
Trial cohort analysis.
- How many people, animals or samples were studied?
21,626.
- What was actually found?
83.7% -> 90.4%.
- How large was the observed effect?
+6.7 points.
- What do the results mean in everyday life?
Childhood leukaemia is usually curable with treatment.
- What are the study's limitations?
Trial patients.
- What does it say about Elawady's specific claim?
Benefit side.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Survival outside trials.
-
Immunotherapy lets half of patients with advanced melanoma live at least five years
Larkin J et al.. N Engl J Med 2019 · PMID 31562797 · DOI 10.1056/NEJMoa1910836Randomised controlled trialindependent cross-checkabstract checked5-year survival 52% with combined immunotherapy vs 26% with the older drug.
Long survival in metastatic disease
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Report 5-year survival.
- How was the study done?
RCT.
- How many people, animals or samples were studied?
Advanced melanoma.
- What was actually found?
52% 5-year OS.
- How large was the observed effect?
HR 0.52.
- What do the results mean in everyday life?
The immune system can fight cancer when helped.
- What are the study's limitations?
Industry funding.
- What does it say about Elawady's specific claim?
Contradicts immune claim.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Effect in other cancers.
-
Cancer death rates in the USA keep falling
Siegel RL et al.. CA Cancer J Clin 2024 · PMID 38230766 · DOI 10.3322/caac.21820Otherindependent cross-checkabstract checkedMore than 4 million cancer deaths averted since 1991 thanks to less smoking, earlier detection and better treatment.
Mortality declining
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Report cancer statistics.
- How was the study done?
Registry data.
- How many people, animals or samples were studied?
US population.
- What was actually found?
Declining mortality.
- How large was the observed effect?
>4 million deaths averted.
- What do the results mean in everyday life?
Prevention and treatment both work.
- What are the study's limitations?
Descriptive.
- What does it say about Elawady's specific claim?
Benefit context.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Share due to treatment alone.
-
Late deaths among childhood-cancer survivors have fallen as treatment became gentler
Armstrong GT et al.. N Engl J Med 2016 · PMID 26761625 · DOI 10.1056/NEJMoa1510795Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessment★ key study15-year death rate after surviving 5 years dropped from 12.4% to 6.0% between the 1970s and 1990s.
Most 5-year survivors are alive decades later
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Track late mortality across eras.
- How was the study done?
Cohort, 34,033 survivors.
- How many people, animals or samples were studied?
34,033.
- What was actually found?
41% of late deaths health-related; mortality halved over time.
- How large was the observed effect?
12.4% -> 6.0%.
- What do the results mean in everyday life?
Late effects are real and being reduced.
- What are the study's limitations?
Observational era comparison; cannot measure improvements in medical care; treatment data imputed for 29%; shorter follow-up for the 1990s.
- What does it say about Elawady's specific claim?
Supports burden and shows progress.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
That treatment should be avoided.
-
Testicular cancer survivors face late effects but almost all survive
Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832Narrative reviewcited by the Tayebat archivefull text, structured risk-of-bias assessment10-year relative survival is 95%; heart disease and second cancers are the main serious late effects.
Curable cancer with cisplatin
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Review late effects.
- How was the study done?
Narrative review.
- What was actually found?
Multiple late effects.
- What do the results mean in everyday life?
Long-term check-ups and healthy lifestyle.
- What are the study's limitations?
Narrative review without systematic search or quality appraisal; much evidence from older treatment eras.
- What does it say about Elawady's specific claim?
Mixed.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Quantitative risks.
-
Lung CT screening trial (NLST)
National Lung Screening Trial Research Team; Aberle DR et al.. N Engl J Med 2011 · PMID 21714641 · DOI 10.1056/NEJMoa1102873Randomised controlled trialindependent cross-checkabstract checked★ key studyScreening heavy smokers with low-dose CT cut lung-cancer deaths by 20% and deaths from any cause by 6.7%.
Early detection plus treatment lowered lung-cancer and all-cause mortality in an RCT.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test whether early detection saves lives
- How was the study done?
Randomised trial
- How many people, animals or samples were studied?
53,454 high-risk adults
- What was actually found?
Fewer lung-cancer deaths with CT screening
- How large was the observed effect?
247 vs 309 deaths per 100,000 person-years
- What do the results mean in everyday life?
Finding cancer early and treating it can prevent deaths
- What are the study's limitations?
Many false alarms; some overdiagnosis
- What does it say about Elawady's specific claim?
Contradicts 'early diagnosis makes you die early'
- Do the results apply to Germany and Europe?
Moderate (European trial found similar results)
- What can explicitly not be concluded from this study?
Does not apply to low-risk people
-
Chemotherapy vs supportive care alone in advanced lung cancer
NSCLC Meta-Analyses Collaborative Group. J Clin Oncol 2008 · PMID 18678835 · DOI 10.1200/JCO.2008.17.7162Meta-analysisindependent cross-checkabstract checked★ key studyChemotherapy raised 1-year survival from 20% to 29%.
Even in incurable cancer, treatment buys measurable time, which the claim dismisses.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure survival benefit of chemotherapy in advanced lung cancer
- How was the study done?
IPD meta-analysis of randomised trials
- How many people, animals or samples were studied?
2714 patients in 16 trials
- What was actually found?
23% lower risk of death
- How large was the observed effect?
HR 0.77; 1-year survival 20% -> 29%
- What do the results mean in everyday life?
About 1 in 11 treated patients is alive at 1 year because of chemotherapy
- What are the study's limitations?
Older drugs; modest absolute gain
- What does it say about Elawady's specific claim?
Contradicts 'oncology only buys time' as meaningless and 'chemo often does not help' in fit patients
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Does not show benefit for frail patients in their last weeks
-
Childhood cancer survival in Egypt
Soliman RM et al.. Int J Cancer 2021 · PMID 32997796 · DOI 10.1002/ijc.33321Cohort studyindependent cross-checkabstract checked★ key studyAt Egypt's main children's cancer hospital, 72% of children were alive 5 years after diagnosis, and survival improved over time.
Egyptian survival figures and rising trends contradict 'oncology only buys time'.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure Egyptian childhood cancer survival
- How was the study done?
Hospital cohort
- How many people, animals or samples were studied?
14,808 children
- What was actually found?
Survival rising
- How large was the observed effect?
5-y OS 72.1%; 69.6% -> 74.2%
- What do the results mean in everyday life?
Treatment cures most children in Egypt too
- What are the study's limitations?
Single hospital; no untreated group
- What does it say about Elawady's specific claim?
Contradicts the futility claim
- Do the results apply to Germany and Europe?
High (Egyptian data)
- What can explicitly not be concluded from this study?
Cannot isolate the effect of each treatment
No study in this group is marked as key.
Studies with mixed or unclear results (3)
-
Why rising cancer survival rates can mislead
Welch HG et al.. JAMA 2000 · PMID 10865276 · DOI 10.1001/jama.283.22.2975Ecological studyindependent cross-checkabstract checked★ key studySurvival gains over time matched rising diagnosis rates, not falling death rates.
Supports the narrow point that rising survival rates can mislead (lead-time, overdiagnosis); does not support 'early diagnosis makes you die early' or 'treatment only buys time'.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Check whether survival trends reflect real progress
- How was the study done?
Analysis of US cancer statistics 1950-1995
- How many people, animals or samples were studied?
20 tumour types
- What was actually found?
Survival changes tracked diagnosis, not deaths
- How large was the observed effect?
r=0.00 with mortality; r=+0.49 with incidence
- What do the results mean in everyday life?
Earlier diagnosis can make survival look longer without people living longer
- What are the study's limitations?
Ecological, old data
- What does it say about Elawady's specific claim?
Partly supports scepticism about survival statistics; does not show early diagnosis shortens life
- Do the results apply to Germany and Europe?
Moderate
- What can explicitly not be concluded from this study?
Cannot judge any specific treatment
-
How much does chemotherapy add to cancer survival overall?
Morgan G et al.. Clin Oncol (R Coll Radiol) 2004 · PMID 15630849 · DOI 10.1016/j.clon.2004.06.007Otherindependent cross-checkabstract checked★ key studyAcross all adult cancer patients, the authors estimated that about 2% are alive at 5 years because of chemotherapy alone.
Often cited to argue oncology is futile; the metric does not measure benefit in treated patients.
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Estimate population-level contribution of chemotherapy
- How was the study done?
Modelling from trials and registries
- How many people, animals or samples were studied?
22 cancer types
- What was actually found?
About 2.3% of all patients
- How large was the observed effect?
2.1-2.3%
- What do the results mean in everyday life?
Chemotherapy is not the main reason most people survive cancer (surgery and early detection are)
- What are the study's limitations?
Denominator includes patients who never needed chemotherapy
- What does it say about Elawady's specific claim?
Gives partial support to scepticism, but not to refusing indicated treatment
- Do the results apply to Germany and Europe?
Low
- What can explicitly not be concluded from this study?
Cannot show chemotherapy is useless for a given patient
-
Many new cancer drugs approved without proof of longer or better life
Davis C et al.. BMJ 2017 · PMID 28978555 · DOI 10.1136/bmj.j4530Otherindependent cross-checkabstract checkedOf 68 new cancer-drug approvals in Europe, only about half showed a survival or quality-of-life benefit after 5 years.
Supports that some treatments only add months; does not support 'survival rates are meaningless'.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Check evidence behind new cancer drugs
- How was the study done?
Cohort of EMA approvals
- How many people, animals or samples were studied?
68 indications 2009-13
- What was actually found?
Many approvals with uncertain benefit
- How large was the observed effect?
35% had OS benefit at approval
- What do the results mean in everyday life?
Ask what a new drug adds; proven standard treatments are different
- What are the study's limitations?
New drugs only
- What does it say about Elawady's specific claim?
Partly supports scepticism
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Does not apply to established curative chemotherapy or radiotherapy
No study in this group is marked as key.
Regional context
Germany / EU
Same.
Egypt
At Children's Cancer Hospital Egypt, 5-year survival of 14,808 children treated for cancer was 72.1% and rose over 2007-2017, although it remained about 9-11 points below England and the USA (I-CHM-125).
What applies in my country?
General scientific assessment
False This claim is false: randomised trials using death rates, which earlier diagnosis cannot distort, show that early detection and treatment save lives and many patients are cured; it is correct only that survival-rate trends can be inflated by earlier diagnosis and overdiagnosis.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.. EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.. EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2
- Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.. Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.. Larkin J et al.. N Engl J Med 2019 · PMID 31562797 · DOI 10.1056/NEJMoa1910836
- Cancer statistics, 2024.. Siegel RL et al.. CA Cancer J Clin 2024 · PMID 38230766 · DOI 10.3322/caac.21820
- Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer.. Armstrong GT et al.. N Engl J Med 2016 · PMID 26761625 · DOI 10.1056/NEJMoa1510795
- Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.. Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832
- Reduced lung-cancer mortality with low-dose computed tomographic screening.. National Lung Screening Trial Research Team; Aberle DR et al.. N Engl J Med 2011 · PMID 21714641 · DOI 10.1056/NEJMoa1102873
- Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.. NSCLC Meta-Analyses Collaborative Group. J Clin Oncol 2008 · PMID 18678835 · DOI 10.1200/JCO.2008.17.7162
- Temporal trends in childhood cancer survival in Egypt, 2007 to 2017: A large retrospective study of 14 808 children with cancer from the Children's Cancer Hospital Egypt.. Soliman RM et al.. Int J Cancer 2021 · PMID 32997796 · DOI 10.1002/ijc.33321
- Are increasing 5-year survival rates evidence of success against cancer?. Welch HG et al.. JAMA 2000 · PMID 10865276 · DOI 10.1001/jama.283.22.2975
- The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.. Morgan G et al.. Clin Oncol (R Coll Radiol) 2004 · PMID 15630849 · DOI 10.1016/j.clon.2004.06.007
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.. Davis C et al.. BMJ 2017 · PMID 28978555 · DOI 10.1136/bmj.j4530